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Extracellular ATP interacts with P2 purinergic receptors
that are expressed on a wide spectrum of tissues. Two classes of
P2 receptors have been identified, the G-protein-coupled seventransmembrane P2Y receptors and the P2X ligand-gated cation
channels (1). Seven members of the P2X receptor family have
been cloned, which share the same predicted structure with
two transmembrane-spanning domains, an extracellular loop
and intracellular N- and C-terminal tails. The P2X7 receptor
(P2X7R)1 differs from the other P2X receptors; in particular, its
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C-terminal domain is 200 amino acids longer and it does not
heteropolymerize with other members of the P2X family (2).
Brief exposure to millimolar concentrations of ATP in its fully
dissociated tetra-anionic form, ATP4⫺, opens cation-specific ion
channels. Prolonged triggering of P2X7R results in the formation of non-selective membrane pores permeable to molecules of
molecular mass up to 900 Da. Formation of the non-selective
pore is dependent on the cytoplasmic C-terminal domain of
P2X7R (3–5). However, it is still unclear whether it results
from dilatation of the P2X7R-induced cation channel or from
interaction of P2X7R with a distinct channel protein, which
allows the entry of larger molecules (reviewed in Ref. 6).
Depending on the cell type, numerous physiological functions have been attributed to P2X7R; notably, formation of
giant cells (7, 8), activation of caspase 1 (9, 10), and rapid
release of mature interleukin-1␤ from macrophages (11, 12),
shedding of membrane molecules such as L-selectin (13, 14)
and CD23 (13), and killing of various intracellular pathogens in
macrophages (15–17).
In most cells that express the P2X7R, sustained stimulation
with ATP leads to membrane blebbing and cell death (18, 19).
In particular, cell death has been observed in different cells of
hematopoietic origin such as lymphocytes (20), thymocytes (21,
22), macrophages (23, 24), and dendritic cells (25, 26). The
physiological significance of cell death mediated by the ligation
of P2X7R by ATP remains to be determined. A potential role for
ATP in programmed cell death underlying positive and negative selection of immature thymocytes during thymus development has been suggested by Chvatchko et al. (27). In in vitro
dexamethasone- or in vivo superantigen-induced apoptosis,
P2X1R is up-regulated and P2X1R antagonists inhibit thymocyte death, suggesting that the elimination of self-reactive thymocytes may be mediated by the P2X1R (27). On the other
hand, death by neglect may be due to one or more pyridoxalphosphate-6-azophenyl-2⬘,4⬘-disulfonic acid-sensitive receptors, i.e. P2X1R, -2R, and/or -7R (28). However, the role of
P2X1R in negative selection has been challenged by Koshiba
et al. (29), who reported that mouse thymocytes treated with
dexamethasone or anti-CD3 mAb respond by up-regulating
P2Y2R mRNA expression but not modifying P2X1R mRNA
transcripts. Thus, the potential role of ATP in programmed cell
death in the thymus still remains elusive.
P2X7R stimulation triggers several intracellular signaling
pathways. Thus, in macrophages (30) and thymocytes (31),
calcium-dependent phospholipase D activation is observed, but
this enzymatic activity is not involved in cell death. The role of

4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine;
PARP, poly(ADP-ribose) polymerase; HMGB1, high-mobility group
box 1 protein; MEK, MAP kinase kinase; mAb, monoclonal antibody.
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Extracellular ATP (ATPe) binds to P2X7 receptors
(P2X7R) expressed on the surface of cells of hematopoietic lineage, including murine thymocytes. Activation of
P2X7R by ATPe results in the opening of cation-specific
channels, and prolonged ATPe exposure leads to the
formation of non-selective pores enabling transmembrane passage of solutes up to 900 Da. In the presence of
ATPe, P2X7R-mediated thymocyte death is due primarily to necrosis/lysis and not apoptosis, as measured by
the release of lactate dehydrogenase indicative of a loss
of plasma membrane integrity. The present study is focused on the identification of P2X7R signaling mediators in ATP-induced thymocyte necrosis/lysis. Thus, extracellular signal-regulated protein kinase 1/2 (Erk1/2)
phosphorylation was found to be required for cell lysis,
and both events were independent of ATP-induced calcium influx. P2X7R-dependent thymocyte death involved the chronological activation of Src family tyrosine kinase(s), phosphatidylinositol 3-kinase, the
mitogen-activated protein (MAP) kinaseErk1/2 module,
and the proteasome. Although independent of this signaling cascade, non-selective pore formation may modulate ATP-mediated thymocyte death. These results
therefore suggest a role for both activation of MAP kinaseErk1/2 and non-selective pore opening in P2X7R-induced thymocyte death.

P2X7R Signaling Pathways in Thymocyte Death

MATERIALS AND METHODS

Animals—Four- to eight-week-old C57BL/6 and BALB/c mice were
purchased from Charles River Laboratories. P2X7R-deficient C57BL/6
mice were obtained from Pfizer Inc.
Reagents—ATP, dexamethasone, oxidized ATP (o-ATP), and lactate
dehydrogenase (LDH) detection kits were purchased from Sigma. Rapamycin, phorbol 12-myristate 13-acetate, genistein, 4-amino-5-(4-chlorophenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2), wortmannin,
LY294002, okadaic acid, U0124, U0126, SB 203580, SP 600125, anisomycin, lactacystin, cycloheximide, actinomycin D, and the fluorogenic
peptide substrate, Suc-Leu-Leu-Val-Tyr-AMC, were purchased from
Calbiochem. EtBr and all cell culture media reagents, except RPMI
1640 without calcium, were obtained from Invitrogen. RPMI 1640 without calcium was purchased from BIO MEDIA. YO-PRO-1 iodide was
from Molecular Probes. All other reagents were obtained from Sigma.
Antibodies—The following antibodies were used for immunoprecipitation or Western blotting: unconjugated rabbit anti-Erk1/2 (pTpY185/
187), anti-JNK1/2 SAPK(pTpY183/185), anti-p38 (pTpY180/182), antiSrc (pY418) phosphospecific antibodies (BIOSOURCE International),
rabbit anti-Akt (pS473) antibody (Cell Signaling), goat anti-actin (I-19),
rabbit anti-Erk1/2 (Zymed Laboratories Inc.), rabbit anti-p38 (C20),
rabbit anti-c-Src (SRC2), goat anti-Akt1, mouse monoclonal anti-Lck
(3A5), mouse monoclonal anti-Fyn (15) antibodies (Santa Cruz Biotechnology), mouse mAb anti-poly(ADP-ribose) polymerase (PARP) (Ab-2,
Oncogene Research Products), affinity-purified rabbit anti-high mobility group box 1 (HMGB1) antibody (BD Pharmingen), affinity-purified
rabbit anti-C-terminal region of rat P2X7R (Alomone Laboratories).
Affinity-purified goat anti-Rabbit IgG coupled to peroxidase (Rockland
Immunochemicals)-, goat anti-mouse IgG-coupled to peroxidase-, and
mouse monoclonal anti-goat/sheep IgG-peroxidase-conjugated antibodies (Sigma-Aldrich) were used as secondary antibodies for Western blot
analyses.
Measurement of LDH Release—In most experiments, mouse thymocytes were preincubated in culture medium without fetal calf serum for
1 h with inhibitors, unless otherwise specified in the figure legends,
before addition of 1 mM ATP for 2 h. Cell lysis was quantified by
measuring the release of LDH or HMGB1. Mouse thymocytes (5 ⫻ 106)
were incubated in 0.5 ml RPMI containing 1 mg/ml of bovine serum
albumin at 37 °C for various lengths of time. Cells were centrifuged at

200 ⫻ g for 10 min, and supernatants were tested for LDH release using
the oxidation reaction of ␤-NADH in the presence of pyruvate (Sigma
kit for LDH). The initial rate of absorbance decrease was measured in
an automatic readout spectrophotometer at  ⫽ 340 nm (38).
Immunoprecipitation—Ten million thymocytes were lysed in 0.2 ml
of lysis buffer containing 50 mM phosphate buffer, pH 7.4, 0.15 M NaCl,
1% Triton X-100, 5 mM EDTA, 30 mM sodium pyrophosphate, 50 mM
sodium fluoride, 30 mM sodium pervanadate, at 4 °C. Cells were incubated 30 min on ice. Lysates were centrifuged at 12,000 ⫻ g for 15 min
at 4 °C. Equal amounts of cell lysates were incubated overnight with
anti-Lck or anti-Fyn at 2 g/ml. To precipitate immune complexes,
Protein-G-Sepharose was added for 2 h. Immune complexes bound to
Protein-G-Sepharose were washed three times and resuspended in
loading buffer containing ␤-mercaptoethanol.
Western Blot Analyses—Lysates or immunoprecipitates from mouse
thymocytes were analyzed by SDS-PAGE and transferred to nitrocellulose membranes, which were blocked with 3% nonfat milk in Trisbuffered saline containing 0.2% Tween 20 for 1 h at 37 °C. Blots were
immunostained with primary antibodies at 4 °C overnight and probed
with secondary antibodies conjugated to horseradish peroxidase. Specific
bands were visualized by enhanced chemiluminescence (PerkinElmer
Life Sciences).
Analysis of Proteasome Activity—To measure proteasome activity in
intact thymocytes, 2.5 ⫻ 106 cells were suspended in 100 l of phosphate-buffered saline containing 20 M D-glucose and 1 mg/ml bovine
serum albumin in a flat bottom 96-well plate. Cells were incubated or
not with inhibitors for 1 h at 37 °C and treated with 1 mM ATP for 2 h.
The fluorogenic peptide substrate for chymotrypsin-like proteasome
activity, Suc-Leu-Leu-Val-Tyr-AMC, was then added at 20 M, and the
plate was incubated at 37 °C for an additional 2 h. Substrate conversion
was measured with a spectrofluorometer (Wallac 1420), using an excitation wavelength of 390 nm, and measuring fluorescence at an emission wavelength of 460 nm.
Non-selective Pore Formation—Thymocytes were incubated 15 min
at 37 °C in the presence of ATP (1 mM) and YO-PRO-1 (2 M) in assay
buffer containing 280 mM sucrose, 10 mM HEPES (pH 7.4), 5 mM
N-methyl-D-glucamine, 5.6 mM KCl, 10 mM D-glucose, 1 mM CaCl2 (39).
Cells were pelleted for 10 min at 200 ⫻ g and incubated with propidium
iodide (0.5 g/ml) in assay buffer at 4 °C. Cell suspensions were then
analyzed by flow cytometry.
For EtBr uptake experiments, 2.5 ⫻ 106 thymocytes were suspended
in 100 l of the same assay buffer containing 10 g/ml ethidium bromide in a flat bottom 96-well plate. ATP (1 mM) was added, and fluorescence was monitored for 40 min at 37 °C in the spectrofluorometer
using an excitation wavelength of 485 nm and an emission wavelength
of 615 nm.
Real-time PCR Assays—Briefly, 2 g of total RNA, extracted from
thymocytes using TRIzol reagent (Invitrogen), were reverse-transcribed
using SuperScript First-Strand Synthesis system for reverse transcription-PCR (Invitrogen). The quantitative real-time PCR reactions were
performed using LightCycler FastStart DNA MasterPlus SYBR Green I
mix (Roche Applied Science) in a LightCycler 2.0 (Roche Applied Science). P2X7R RNA expression data were normalized to that of actin.
The following mouse P2X7R and actin primers were used: P2X7R forward, 5⬘-TTCCAGGAAGCAGGAGAGAA-3⬘; P2X7R reverse, 5⬘-ATACTTCAACGTCGGCTTGG-3⬘; actin forward, 5⬘-GCTACAGCTTCACCACCACA-3⬘; actin reverse, 5⬘-AAGGAAGGCTGGAAAAGAGC-3⬘.
RESULTS

ATP-induced Thymocyte Death—ATP-treated thymocytes
undergo cell lysis and apoptosis, as assessed, respectively, by
the release of cytosolic lactate dehydrogenase (LDH) (Fig. 1A)
(31) and caspase-dependent DNA fragmentation (31). To further elucidate the basis for cell lysis, we took advantage of two
assays that discriminate between the two types of cell death,
namely, the release of HMGB1, a chromatin-associated nuclear
protein that is liberated into the cytosol of necrotic but not
apoptotic cells (40); and the cleavage of PARP, a nuclear protein that is a specific substrate of caspase-3 and is an indicator
of apoptotic cell death. We thus determined the kinetics of
these two events in thymocytes exposed to an optimal dose of
ATP. As can be seen in Fig. 1B, HMGB1 is detected as early as
2 h following ATP stimulation, and increases until 5 h of
culture. In comparison, dexamethasone, a known apoptotic
agent for thymocytes, induces a significantly reduced level of
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P2X7R in controlling protein kinase activities (32–34), the generation of superoxide (35), as well as activation of transcriptional factors (36, 37) has been tested in various cellular models. However, the relationship between these biochemical
events and cell death has not been fully characterized. A role
for caspase-1 in P2X7R-mediated cell death has been established for macrophages stimulated by lipopolysaccharide. In
this model, brief exposure of macrophages to ATP leads to
death by two different pathways, one of which is lipopolysaccharide-independent, and the other, lipopolysaccharide-induced and requiring caspase-1 (24).
In murine thymocytes, P2X7R activation by ATP leads to
death via both caspase-dependent apoptosis, albeit a minor
component of cells dying, and, predominantly, via necrosis/
lysis (31), but the mechanisms of death have not been elucidated. We therefore focused our study on the intracellular
signaling events occurring during thymocyte death following
in vitro ATP treatment. We show that stimulation of P2X7R
in thymocytes induces the activation of the three mitogenactivated protein (MAP) kinase modules, extracellular-signal
regulated kinases 1/2 (Erk1/2), c-Jun N-terminal kinases 1/2
(JNK1/2), and p38 kinases. However, only the MAP kinaseErk1/2 module is necessary for calcium-independent necrosis/lysis of thymocytes. Using specific inhibitors of various
enzymes, we determined that thymocyte death requires the
sequential activation of one or more Src family tyrosine kinases, phosphatidylinositol 3-kinase (PI3K), the extracellular signal-regulated kinases 1/2, and the proteasome. Formation of the non-selective pore is independent of this signaling
pathway, and in particular, of the activation of the MAP
kinaseErk1/2 module, but both pore formation and the signaling pathway contribute to thymocyte death.
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HMGB1 release during the same time. Cleavage of PARP is
detected between 4 and 5 h following ATP treatment, and
though to a greater extent than the untreated control, is much
diminished compared with dexamethasone-treated thymocytes
(Fig. 1C). These results indicate that the effector phase of
thymocyte lysis is well underway 2 h after ATP treatment. The
involvement of various death effector molecules and signaling
pathways in subsequent experiments on thymocyte ATP-induced lysis was therefore determined at the 2-h time point.
Activation of the MAP KinaseErk1/2 Pathway Is Required for
ATP-induced Thymocyte Death—The role of the various MAP
kinase pathways in thymocyte lysis elicited by ATP was
defined using specific inhibitors of the Erk1/2, p38 or JNK
modules. Strong inhibition of LDH release was only observed
after pre-treatment of thymocytes with 20 M U0126, a
MEK1/2 pharmacologic inhibitor. At the same dose, U0124, a
negative control for U0126; SB 203580, an inhibitor of p38
kinase; and SP 600125, an inhibitor of JNK kinases, did not
modulate cell death (Fig. 2A). ATP stimulation of thymocytes
led to phosphorylation of Erk1/2, and the MEK inhibitor
efficiently prevented this activation (Fig. 2C). Phosphorylation of Erk1/2 peaked at 15 min after ATP addition, then
decreased rapidly at 30 min (Fig. 2B). The p38 and JNK1/2
kinases were also activated, and their phosphorylation increased over time (Fig. 2B). Although unable to inhibit LDH
release from thymocytes treated with ATP, the specific inhibitors of the p38 and JNK pathways blocked anisomycin-induced phosphorylation of the two kinases (data not shown).
Stimulation of thymocytes by ATP thus leads to cell death
requiring activation of only the Erk1/2 pathway.
The protein phosphatases 1 and 2A are not involved in ATPmediated thymocyte lysis, because pretreatment with okadaic
acid, an inhibitor of both phosphatases, not only did not pre-

FIG. 2. The MAP kinase Erk1/2 is involved in ATP induced cell
death. A, the effects of various inhibitors of MAP kinases or MAP
kinase-kinase on ATP-induced LDH release. Thymocytes were preincubated for 1 h at 37 °C with 20 M U0126, a specific inhibitor of MEK1/2;
U0124, an inactive analog of U0126; SB 203580, an inhibitor of the p38
MAP kinase; SP600125, an inhibitor of the JNK MAP kinases; or with
an equivalent volume of Me2SO (vehicle control). Thymocytes were then
treated with 1 mM ATP for 2 h. The experiments were performed on 3
separate days, and the values represent the mean ⫾ S.D. of three
experiments. B, kinetic analysis of phosphorylation of the Erk1/2,
JNK1/2, and p38 MAP kinases after P2X7R stimulation with 1 mM
ATP. Thymocytes were treated with ATP for increasing lengths of time
at 37 °C. Proteins from thymocyte lysates were separated on 10% SDSPAGE and immunoblotted for phospho-threonine and phospho-tyrosine
with anti-Erk1/2 (pTpY 185/187) (B, first panel) or anti-p38 (pTpY
180/182) (B, third panel) antibodies, or with anti-JNK1/2 (pTpY 183/
185) antibody (B, fifth panel). After stripping, the three blots were
probed with anti-total Erk1/2 (B, second and last panels) or anti-total
p38 (B, fourth panel) antibodies to check for equal loading of gels. In C,
thymocytes preincubated or not with U0126 were then treated with 1
mM ATP or control buffer for 15 min at 37 °C. Proteins from cell lysates
were separated on 10% SDS-PAGE and immunoblotted for phosphothreonine and phospho-tyrosine with anti-Erk1/2 antibody (pTpY 185/
187) (C, top panel). After stripping, the blot was probed for total antiErk1/2 (C, bottom panel). The results shown in B and C are typical of
those obtained in three independent experiments.

vent cell death but instead increased it (Fig. 3A). It should be
noted that, although okadaic acid alone increased significantly
Erk1/2 phosphorylation (Fig. 3B), cell death remained at the
level of control untreated thymocyte cultures (12% LDH release). ATP stimulation of okadaic acid-treated thymocytes
potentiated Erk1/2 phosphorylation by 20%; this value was
calculated with a shorter time of exposure by densitometry
(data not shown). Using the inhibitor of MEK1/2 activities,
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FIG. 1. P2X7R ligation leads to necrosis rather than apoptosis
of thymocytes. A, kinetics of LDH release from thymocytes treated
with 1 mM ATP, 100 nM dexamethasone, or control buffer. The experiments were performed on 3 separate days, and the values represent the
mean ⫾ S.D. of three experiments. B, immunoblots performed with
affinity-purified rabbit anti-HMGB1 antibody on culture supernatants
of thymocytes incubated with 1 mM ATP or control buffer for increasing
lengths of time, or with 100 nM dexamethasone (Dex) for 5 h. C, proteins
from thymocyte lysates incubated with or without 1 mM ATP for increasing lengths of time or 100 nM dexamethasone (Dex) for 5 h were
separated on 7.5% SDS-PAGE and immunoblotted with anti-PARP
antibody (C, top panels). The same blots were stripped and probed for
actin to show equal loading (C, bottom panels). The results shown in B
and C are representative of at least two experiments performed on
different days.

P2X7R Signaling Pathways in Thymocyte Death

U0126, we found that ATP-induced LDH release was much
diminished, whether or not okadaic acid was present (Fig. 3A).
As expected, U0126 strongly inhibited the phosphorylation of
Erk1/2, demonstrating that these MAP kinases are key mediators in ATP-induced cell death.
ATP-induced Erk1/2 Phosphorylation Is Mediated through
the Purinergic Receptor P2X7—Mouse thymocytes express several P2X receptors, including P2X1R, -2R, -6R, and -7R (28). To
identify which P2X receptor may be linked to Erk1/2 activation,
we showed that pretreatment of thymocytes with the P2X7R
antagonist, o-ATP, blocked the appearance of phosphorylated
Erk1/2 following stimulation with ATP (Fig. 4A). Importantly,
we found no activation of Erk1/2 in P2X7R-deficient thymocytes treated with ATP (Fig. 4B). This was not related to a
P2X7R-dependent default in the Erk1/2 pathway itself, because phorbol 12-myristate 13-acetate could still activate
Erk1/2 at identical levels in thymocytes from wild type or
P2X7R-deficient mice (Fig. 4C). Furthermore, we determined
by reverse transcription-PCR that, as in wild type animals,
thymocytes from P2X7R-deficient mice express P2X1R, -2R,
and -6R (data not shown). Taken together, these results indicate that Erk1/2 phosphorylation in murine thymocytes results
from the ligation of P2X7R by ATP.
Role of Calcium in Thymocyte Death Elicited by ATP—The
opening of ion channels leading to a rapid influx into the cytosol
of divalent cations (in particular, Ca2⫹) is characteristic of
P2X7R activation (41). The role of Ca2⫹ in ATP-mediated
P2X7R effects was therefore assessed. As shown in Fig. 5A, the
level of ATP-induced LDH release was not affected by the
absence of extracellular calcium, and Erk1/2 phosphorylation
was identical in thymocytes whether or not calcium was present (Fig. 5B). Thus, stimulation of P2X7R by ATP leads to both
thymocyte lysis and Erk1/2 phosphorylation in a calcium-independent way.
Src family Tyrosine Kinase(s) and PI3K Are Necessary for
P2X7R-dependent Thymocyte Death—Because Src kinases are
involved in T-cell receptor-dependent signal transduction in
thymocytes (reviewed in Ref. 42), their involvement in the

FIG. 4. The MAP kinaseErk1/2 is phosphorylated following
P2X7R stimulation. A, thymocytes were preincubated with 300 M
o-ATP or control buffer for 1 h at 37 °C and then stimulated with 1 mM
ATP for 15 min. B and C, thymocytes from wild type (wt) or P2X7Rdeficient (P2X7°/°) mice were incubated with 1 mM ATP or control
buffer (B) or 1 M phorbol 12-myristate 13-acetate (PMA, C). Proteins
from cellular lysates were separated by SDS-PAGE and immunoblotted
for phospho-threonine and phospho-tyrosine with anti-Erk1/2 (pTpY
185/187) antibody (three top panels of A–C). After stripping, the blots
were probed for total Erk1/2 (three bottom panels of A–C). The results
are representative of three experiments performed on different days.

FIG. 5. P2X7R-induced thymocyte death and phosphorylation of MAP kinaseErk1/2 are calcium independent. A, thymocytes were incubated in complete or Ca2⫹ free RPMI 1640 medium
and stimulated or not with 1 mM ATP for 2 h at 37 °C. Percentage of
LDH release was determined. The experiments were performed on 3
separate days, and the values represent the mean ⫾ S.D. of three
experiments. B, thymocytes treated as above were lysed, and proteins
from cellular lysates were separated on 10% SDS-PAGE. The immunoblot was performed with rabbit anti-Erk1/2 (pTpY 185/187) antibody to detect phosphorylated Erk1/2, and re-probed for total Erk1/2
to show equal loading. The results are representative of three experiments performed on different days.

P2X7R signaling pathway was investigated. The effect of inhibitors of Src kinases on thymocyte death was evaluated, and
the phosphorylation state of Src kinases in cell lysates was
determined, using rabbit anti-Src (pY418) phosphospecific antibodies. Genistein, a broad spectrum tyrosine kinase inhibitor,
and PP2, a selective inhibitor of the Src family tyrosine kinase(s), significantly diminished ATP-induced thymocyte lysis
(Fig. 6A). Src phosphorylation increased in ATP-stimulated
thymocyte lysates, and phosphorylation could be blocked by
PP2, providing additional support for a role of Src family tyrosine kinase(s) in P2X7R-induced thymocyte death (Fig. 6B).
To identify the Src family tyrosine kinase(s) involved in
P2X7R signaling, thymocyte lysates were precipitated with
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FIG. 3. Inhibition of phosphatase activity by okadaic acid potentiates ATP induced cell death and MAP kinaseErk1/2 phosphorylation. A, thymocytes were preincubated with 1 M okadaic acid or
20 M U0126 or both inhibitors for 1 h at 37 °C. After stimulation with
ATP for 2 h, the percentage of LDH release was determined. B, as
above, thymocytes were preincubated with the same inhibitors for 1 h
and stimulated with ATP for 15 min. Proteins from cellular lysates were
separated on 10% SDS-PAGE and immunoblotted for phospho-threonine and phospho-tyrosine with anti-Erk1/2 (pTpY 185/187) antibody
(B, top panel). After stripping, the blot was probed for total Erk1/2
antibody (B, bottom panel). The results are representative of three
experiments performed on different days.
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mAb specific for p56lck and p59fyn, and the immunoprecipitates
were subsequently analyzed with rabbit anti-Src phosphospecific antibodies. Significantly, the two Src-tyrosine kinases
p56lck and p59fyn are known to be recruited during T cell receptor-mediated signal transduction in thymocytes (reviewed in Ref.
42). However, no phosphorylation of either kinase was revealed
in lysates of ATP-stimulated thymocytes (Fig. 6C). It thus appears that neither p56lck nor p59fyn play a role in the transduction pathway activated by ligation of the P2X7R by ATP.
PI4K has been identified by proteomic analysis to be 1 of 11
proteins associated with the purinergic receptor P2X7 (43). To
determine whether PI4K or related kinases participate in the
P2X7R signaling pathway, we treated thymocytes with wortmannin, an inhibitor of PI4K and PI3K, or with LY294002, a
selective inhibitor of PI3K, and measured ATP-triggered LDH
release. A significant decrease in thymocyte lysis was observed

FIG. 7. PI3K is involved in P2X7R-mediated thymocyte death.
A, thymocytes were preincubated with different PI3K inhibitors (wortmannin or LY294002) or the same volume of vehicle control for 1 h at
37 °C. Percentages of LDH release were measured 2 h after ATP addition. B, thymocytes were preincubated with 1 M okadaic acid or 50 M
LY294002 or both for 1 h at 37 °C. Cells were stimulated with 1 mM ATP
or control buffer for 15 min. Proteins from thymocyte lysates were
separated on 10% SDS-PAGE and immunoblotted with anti-phospho
Akt (pS473) antibody (B, top panel). The membrane was stripped and
probed for total Akt with anti-Akt1 (B, bottom panel). The results are
representative of three experiments performed on different days. C,
thymocytes were pretreated with 100 nM rapamycin or with the same
volume of vehicle control for 1 h at 37 °C. Percentages of LDH release
were determined after stimulation with 1 mM ATP for 2 h. The experiments were performed on 3 separate days, and the values represent the
mean ⫾ S.D. of three experiments.

for both inhibitors (Fig. 7A). The phosphorylation status of Akt,
one of the target enzymes downstream of PI3K, was then
examined. As shown in Fig. 7B, ATP did not activate Akt,
unlike okadaic acid, and the phosphorylation induced by okadaic acid was inhibited by the selective inhibitor of PI3K. The
lack of effect on thymocyte lysis of rapamycin, a highly specific
inhibitor of mammalian target of rapamycin, a substrate of
Akt, confirms the inability of ATP to trigger the phosphorylation and activation of Akt (Fig. 7C). These results show that,
although PI3K is involved in the P2X7R biochemical death
pathway, the effective downstream protein kinases do not include Akt.
Role for the Proteasome in ATP-mediated Thymocyte Death—
Because some forms of cell death rely on the proteasome and
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FIG. 6. The Src family tyrosine kinase is phosphorylated after
P2X7R stimulation and is involved in P2X7R-mediated thymocyte death. A, thymocytes were preincubated with different tyrosinekinase inhibitors or vehicle control for 1 h at 37 °C. Genistein was used
at 100 M and PP2 at two different concentrations (10 and 20 M). After
stimulation with 1 mM ATP for 2 h at 37 °C, percentages of ATPinduced LDH release were determined. The experiments were performed on 3 separate days, and the values represent the mean ⫾ S.D. of
three experiments. B, thymocytes were preincubated with 20 M PP2 or
control buffer and then stimulated with ATP for 5 min. Proteins from
cellular lysates were separated on 10% SDS-PAGE and immunoblotted
with phosphospecific anti-Src (pY418) antibody. After stripping, the
blot was probed for total Src kinase. C, thymocytes were treated with
ATP or control buffer for 5 min at 37 °C. Cells were lysed in a lysis
buffer containing phosphatase inhibitors (see “Materials and Methods”). The kinases, Lck or Fyn, were specifically immunoprecipitated
with anti-Lck or anti-Fyn mouse mAbs, respectively (C, Lck, left panel;
and Fyn, right panel). Immunoprecipitated kinases were analyzed on
10% SDS-PAGE and immunoblotted with phosphospecific anti-Src
(pY418) antibody. After stripping, the blots were probed for total Lck
with an anti-Lck mouse mAb and for total Fyn with anti-Src antibody.
The results shown in B and C are representative of at least two experiments performed on different days. IP, immunoprecipitation; WB,
Western blot.
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FIG. 9. Different enzymes are involved sequentially in the
P2X7R-mediated thymocyte death pathway. Thymocytes were
treated with control buffer or the inhibitors, PP2 (20 M), LY294002 (50
M), U0126 (20 M), or lactacystin (10 M) for 1 h at 37 °C. After
incubation, they were stimulated with 1 mM ATP for 5 min. Proteins
from cellular lysates were separated on 10% SDS-PAGE and immunoblotted with phosphospecific anti-Src (pY418) antibody (A, upper blot)
or for phospho-threonine and phospho-tyrosine with anti-Erk1/2 (pTpY
185/187) antibodies (B, upper blot). After stripping, the blots were
probed for total Src kinase (A, lower blot) or total Erk1/2 (B, lower blot).
The results shown are representative of three experiments performed
on different days.

NF-B pathway (44 – 47), we examined proteasome function in
ATP-treated thymocytes to determine whether the proteasome
could be involved in thymocyte death downstream of PI3K.
Chymotrypsin-like proteasome activity was measured using a
fluorogenic peptide substrate and found to increase 3-fold in
ATP-treated thymocytes, compared with control cells (Fig. 8A).
Proteasome activation was dependent on P2X7R stimulation,
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FIG. 8. The proteasome plays a role in P2X7R-triggered thymocyte death. A, thymocytes were stimulated with 1 mM ATP or vehicle
control for 2 h and incubated with 20 M of the fluorogenic peptide
substrate, Suc-Leu-Leu-Val-Tyr-AMC, for an additional 2 h at 37 °C.
The increase in fluorescence over time was determined with a spectrofluorometer, as described under “Materials and Methods.” B (left
inset), thymocytes from BALB/c mice were incubated with optimal
concentrations of o-ATP (300 M), U0126 (20 M), or lactacystin (10 M)
for 1 h at 37 °C. After incubation, cells were treated with ATP or control
buffer for 2 h, and the fluorogenic substrate was added for an additional
2 h. The -fold increases in fluorescence after ATP treatment, compared
with unstimulated cells, were determined by measuring the fluorescence in each sample. B (right inset), thymocytes from wild type (wt)
and P2X7R-deficient (P2X7°/°) animals were treated as above. The
-fold increases in fluorescence after ATP stimulation, compared with
resting cells, were determined. C, thymocytes were incubated with 10
M lactacystin or control buffer for 1 h at 37 °C, and then stimulated
with 1 mM ATP for 2 h. Percentages of LDH release were determined.
The experiments were performed on 3 separate days, and the values
represent the mean ⫾ S.D. of three experiments.

because it was not observed in thymocytes pretreated with
o-ATP or derived from P2X7R-deficient mice (Fig. 8B). Pretreatment with lactacystin, a highly specific proteasome inhibitor, prevented lysis of ATP-treated thymocytes (Fig. 8C).
These findings imply an involvement for the proteasome in the
P2X7R signal transduction pathway.
Hierarchy of Activation of Mediators in the P2X7R-dependent
Pathway Leading to Cell Death—The order in which enzymes
involved in the P2X7R signaling cascade are activated was
established by determining the effect of various pharmacological inhibitors on the phosphorylation status of different kinases. P2X7R stimulation with ATP for 5 min led to an increase
in the phosphorylation of Src family kinases. Significantly, this
phosphorylation was inhibited by PP2 but not LY294002,
U0126, or lactacystin (Fig. 9A). These results suggest that Src
kinases are independent or upstream of PI3K, MEK1/2, and
the proteasome. PP2, LY294002, and U0126 blocked the phosphorylation of Erk1/2, whereas lactacystin had no effect (Fig.
9B). The MAP kinase module is thus downstream of Src kinase
and PI3K, but it is independent or upstream of the proteasome.
Both lactacystin and U0126 inhibit the P2X7R-stimulated proteolytic activity of the proteasome (Fig. 8B), indicating that
activation of the proteasome is regulated by the MAP kinaseErk1/2 module and is downstream of MEK1/2.
Non-selective Pore Formation Is Not Modulated by the Mediators of the P2X7R Signaling Pathway—Activation of P2X7R
by extracellular ATP rapidly induces the opening of a nonselective pore. The effect of different inhibitors of the P2X7R
signaling cascade on pore opening was therefore tested. Mouse
thymocytes were incubated with or without the inhibitors and
stimulated or not with 1 mM ATP for 15 min in the presence of
the immunofluorescent YO-PRO-1 iodide and propidium iodide. They were then washed and kept at 4 °C until analyzed
by flow cytometry. As shown in Fig. 10A, ATP induced the
uptake of YO-PRO-1 in about 45% of the thymocytes. This was
related to ATP ligation of P2X7R, because preincubation with
o-ATP reduced the number of YO-PRO-1-positive thymocytes
to 8%. The inhibitors of MEK1/2, Src family kinase(s), PI3K,
and proteasome, had no effect on P2X7R-mediated YO-PRO-1
uptake (Fig. 10B), indicating that pore formation is independent of the ATP-induced intracellular signaling events leading
to thymocyte lysis.
However, this finding does not exclude the possibility that
the non-selective pore may influence activation of the enzymes
involved in the cell death pathway. To address this question,
we took advantage of the Pro-451 to Leu mutation of P2X7R in
C57BL/6 mice, which is responsible for a reduction in ATP-
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FIG. 10. The formation of the non-selective pore is upstream and/or independent of the enzymatic cascade triggered by P2X7R. A,
thymocytes were treated with control buffer or optimal concentrations of o-ATP (300 M) or U0126 (20 M) for 1 h at 37 °C. Cells were then
incubated with 2 M YO-PRO-1 and stimulated with 1 mM ATP (⫹ATP) or control buffer (⫺ATP) for 15 min. Cells were centrifuged and kept on
ice at 4 °C in an assay buffer containing propidium iodide. Propidium iodide-positive cells were excluded, and YO-PRO-1-positive cells were
quantified by flow cytometry. The results shown are representative of three experiments performed on different days. B, percentages of
YO-PRO-1-positive cells are presented as histograms. Thymocytes were treated with control buffer or o-ATP, PP2, LY294002, U0126, or lactacystin
at optimal concentrations for 1 h at 37 °C. Cells were then incubated with 2 M YO-PRO-1 and stimulated with 1 mM ATP (⫹ATP) or control buffer
(⫺ATP) for 15 min. Cells were centrifuged and kept on ice at 4 °C in an assay buffer containing propidium iodide. Propidium iodide-positive cells
were excluded, and YO-PRO-1-positive cells were quantified by flow cytometry. The experiments were performed on 3 separate days, and the values
represent the mean ⫾ S.D. of three experiments.
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FIG. 11. The level of thymocyte death correlates with nonselective pore formation. A, thymocytes from BALB/c, C57BL/6, and
P2X7R-deficient mice were incubated with EtBr and stimulated with 1
mM ATP for increasing lengths of time. EtBr fluorescence of each
sample was monitored for 35 min at 37 °C. For each curve, ATP-dependent EtBr uptake was calculated by subtracting EtBr values of
unstimulated cells from values of ATP-stimulated thymocytes. B, thymocytes from BALB/c and C57BL/6 mice were stimulated or not with 1
mM ATP for 2 h at 37 °C. Percentages of LDH release were determined.
The experiments were performed on 3 separate days, and the values
represent the mean ⫾ S.D. of three experiments. C, thymocytes from
BALB/c and C57BL/6 mice were stimulated with ATP for 15 min at
37 °C. Proteins from cellular lysates were separated on 10% SDS-PAGE
and immunoblotted for phospho-threonine and phospho-tyrosine with
anti-Erk1/2 (pTpY 185/187) antibody (C, top blot). After stripping, the
blots were probed for total Erk1/2 (C, lower blot). The results shown in
A and C are representative of three experiments performed on different
days.

mediated pore formation (4). Pore formation, as assessed by
EtBr uptake after stimulation with various concentrations of
ATP, was compared in thymocytes derived from C57BL/6 and
BALB/c mice. For both strains, the optimal concentration for
pore formation was 1 mM ATP (data not shown), at which
concentration BALB/c thymocytes incorporated twice as much
EtBr as cells from C57BL/6 mice, whereas no EtBr uptake was
detected in P2X7R-deficient cells (Fig. 11A). Likewise, LDH
release from ATP-stimulated BALB/c thymocytes was twice
that observed for C57BL/6 mice (Fig. 11B). However, we found
no differences in P2X7R mRNA levels nor P2X7R expression
between thymocytes from BALB/c and C57BL/6 mice (Fig. 12).
Importantly, Erk1/2 phosphorylation was identical when thymocytes from BALB/c and C57BL/6 mice were compared (Fig.
11C), implying that the non-selective pore does not affect
Erk1/2 activation.
DISCUSSION

The present work was focused on the intracellular signaling
events activated by the ligation of P2X7R by ATP and leading
to cell death in murine thymocytes. Under our experimental

conditions, the main pathway of P2X7R-mediated thymocyte
death was necrosis/lysis, rather than apoptosis. The biochemical events underlying P2X7R signaling were identified following a 2-h stimulation of thymocytes with ATP. At this time
point, there was significant release of HMGB1 in ATP-treated
thymocytes, compared with untreated or dexamethasonetreated thymocytes. HMGB1 is released only by necrotic cells,
whereas in apoptotic cells, even at later stages of cell death,
this nuclear protein is tightly bound to deacetylated histone
(40). Concomitantly, cleavage of PARP, a substrate of
caspase-3, was barely detectable and, compared with dexamethasone-exposed thymocytes, was much reduced even after
a 5-h treatment with ATP. The prevalence of necrosis in
P2X7R-induced thymocyte death agrees with the report of Le
Stunff et al. (31), who found only a slight increase over controls
of ATP-induced terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling-positive thymocytes.
Stimulation of murine thymocytes with ATP induced the
activation of Erk1/2, p38, and JNK1/2 MAP kinase modules.
However, a role in thymocyte death was established for only
Erk1/2, because LDH release was inhibited by U0126, a specific
pharmacological inhibitor of MEK1/2, but not by p38 or JNK
inhibitors. Phosphorylation of Erk1/2 correlated with thymocyte death and was dependent on ATP-stimulated P2X7R. It
was much reduced in thymocytes pre-treated with o-ATP, a
P2X7R antagonist, and was not observed in ATP-treated
P2X7R-deficient thymocytes.
The involvement of Erk1/2 in thymocyte death is intriguing,
because MAP kinase Erk1/2 activation is very often linked with
cell proliferation and differentiation (48). However, Erk1/2
phosphorylation is needed for neuronal cell death induced by
glutamate (49) or genistein (50). Paraptosis mediated by insulin-like growth factor I receptor requires the activation of
Erk1/2 and JNK pathways (51). In addition, during positive
selection in the thymus, production of phosphorylated Erk1/2 is
slow and prolonged, whereas it is potent and short-lived in
thymocytes undergoing negative selection (52, 53).
The activation of the MAP kinase pathways following P2X7R
stimulation is not restricted to murine thymocytes. Phospho-
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FIG. 12. P2X7R mRNA and protein expression is identical in
thymocytes from C57BL/6 and BALB/c mice. A, thymocytes from
C57BL/6 and BALB/c mice were isolated, and RNA was extracted as
described under “Materials and Methods.” 2 g of total RNA was
reverse-transcribed, and P2X7R expression was determined using realtime PCR and normalized to that of actin. B, 1 ⫻ 107 thymocytes from
C57BL/6, BALB/c, and P2X7R-deficient mice were lysed and 40, 20, and
10 g of proteins were separated by SDS-PAGE and transferred to
nitrocellulose membrane. Blots were immunostained with affinity-purified rabbit anti-P2X7R or goat anti-actin antibodies.
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events. In addition, a MEK1/2 inhibitor decreased the ATPmediated chymotrypsin-like activity of the 20 S proteasome,
confirming that the Erk1/2 MAP kinase module is located upstream of the proteasome. Proteasome activation has also been
observed in thymocyte apoptosis induced by ionizing radiation,
glucocorticoids, or T cell receptor cross-linking (44 – 47). In
mouse microglial cell line(s), proteasome activity is required for
ATP-triggered P2X7R NF-B activation and target gene expression (36) but not for apoptotic cell death (20). However, we
found that P2X7R-mediated thymocyte death requires neither
transcription nor translation, suggesting that NF-B may be
activated but does not affect thymocyte death.
In addition to being a ligand-gated ion channel, P2X7R has
the ability to form a non-selective pore after repeated or prolonged ATP stimulation (64). In ATP-treated thymocytes, none
of the P2X7R signaling mediators which we have identified
modulated the formation of the non-selective pore, indicating
that pore formation is independent and/or takes place upstream of the signaling cascade leading to cell death. At variance with our results, a role for second messengers in P2X7R
pore opening, in particular, calcium, p38 MAP kinase, and
MEK, has recently been reported for other cellular models
(56, 57).
To address the issue of a link between P2X7R-mediated
thymocyte death and pore formation, we compared these
events in BALB/c and C57BL/6 thymocytes. Although the
P2X7R of C57BL/6 bears a Pro-451 to Leu mutation that impairs non-selective pore formation (4), we found no differences
between the two mouse strains in terms of P2X7R mRNA and
protein expression. We have interpreted the large increase in
pore formation and thymocyte lysis observed in BALB/c, compared with C57BL/6 thymocytes, as indicating that thymocyte
death correlates with non-selective pore formation. Interestingly, phosphorylation of Erk1/2 was identical in ATP-treated
thymocytes from both mouse strains, providing additional support for non-selective pore formation being unrelated to MAP
kinaseErk1/2 activation.
P2X7R-triggered reversible phosphatidylserine exposure on
thymocytes also occurs independently of Erk1/2 activation, because it was not abolished by inhibitors of the Src family
tyrosine kinase(s) or MEK1/2 (data not shown).
In summary, the C-terminal region of P2X7R regulates phosphatidylserine exposure (4) and non-selective pore formation
(3–5). These two events are independent of the signaling pathway leading to Erk1/2 activation, whose control may depend on
the N-terminal region of P2X7R (55). To the best of our knowledge, this is the first report implicating a role for both activation of MAP kinaseErk1/2 and non-selective pore opening in
P2X7R-mediated thymocyte death.
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